Sponsor: Spectrum Pharmaceuticals, Inc.
A phase 2 trial of tyrosine kinase inhibitor poziotinib for patients with metastatic non-small cell lung cancer containing EGFR or HER2 exon 20 mutation that have undergone at least one prior line of therapy for metastatic disease.